Clinical trialNCT00015548CompletedInterventional

CATIE-Alzheimer's Disease Trial

SponsorNational Institute of Mental Health (NIMH)Enrollment450Alzheimer's Disease

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The CATIE Alzheimer's Disease Trial is part of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project. The study is for people with Alzheimer's disease who are having trouble with their thinking or behavior. In particular, this study is trying to find out the best treatment for people who have hallucinations (seeing or hearing things that aren't there), delusions (false beliefs), or agitation. The design of the trial helps to increase the chance that participants in the study receive a medication that helps them. The study uses three medications known as atypical antipsychotics (olanzapine, quetiapine, risperidone), which are the newest medications that are currently available for treating these problems. Participants may also receive an antidepressant (citalopram). The trial lasts for 36 weeks. Participants are given a thorough evaluation at no cost to ensure that this study is appropriate. In addition, the caregiver, family member, or friend who comes with the participant will be offered an educational program about Alzheimer's disease.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Lon Schneider, MD
University of Southern California
Principal Investigator
clinicaltrials.gov ↗
Pierre Tariot, MD
University of Rochester
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Tuscaloosa Va Medical Center
Tuscaloosa, Alabama, United States
University of California, Irvine Medical Center
Irvine, California, United States
University of California, Los Angeles, Va Medical Center
Los Angeles, California, United States
University of Southern California Dept of Psychiatry& Behavioral Sciences
Los Angeles, California, United States
University of California-San Diego, Va Medical Center
San Diego, California, United States
Stanford University School of Medicine
Stanford, California, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Mental Health Advocates, Inc.
Boca Raton, Florida, United States
Berma Research Group
Hialeah, Florida, United States
University of South Florida Suncoast Gerontology Center
Tampa, Florida, United States
Palm Beach Neurology/premiere Research Institute
West Palm Beach, Florida, United States
Emory University - Wesley Woods Health Center
Atlanta, Georgia, United States
University of Hawaii
Honolulu, Hawaii, United States
Northwestern University Medical School
Chicago, Illinois, United States
Southern Illinois School of Medicine
Springfield, Illinois, United States
University of Iowa College of Medicine
Iowa City, Iowa, United States
Louisiana State University Health Sciences Center
Shreveport, Louisiana, United States
Johns Hopkins University
Baltimore, Maryland, United States
Millennium Psychiatric Associates
St Louis, Missouri, United States
University of Medicine and Dentistry of New Jersey
Piscataway, New Jersey, United States
University of Medicine and Dentistry of New Jersey-Stratford
Stratford, New Jersey, United States
Columbia University
New York, New York, United States
Mount Sinai School of Medicine
New York, New York, United States
Global Research and Consulting
Olean, New York, United States
Monroe Community Hospital
Rochester, New York, United States
Staten Island University Hospital
Staten Island, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
University Hospital Health Systems-Laurelwood Hospital
Willoughby, Ohio, United States
Va Medical Center
Coatesville, Pennsylvania, United States
Mental Illness Research Education and Clinical Center
Philadelphia, Pennsylvania, United States
Medical University of South Carolina
North Charleston, South Carolina, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Southwestern Vermont Medical Center- the Memory Clinic
Bennington, Vermont, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Citalopram →Olanzapine →Quetiapine →Risperidone →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Mar 2001
Primary completion: —
Completion: 31 Oct 2004
Last update posted: 17 Jun 2015
Registered enrollment: 450
Registry id: NCT00015548

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.